Candel Therapeutics, Inc.

CADL

Healthcare|Biotechnology|US

$8.75

+0.71 (+8.83%)

DCF Value

$2.20

Tangible Book / Share

$1.70

Cash / Share

$2.72

Next Earnings Report

Nov 12, 2026

EPS est. -$0.34

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Feb 20, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (3)

Jan 2027

Est. completion

P1Malignant Glioma of Brain

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT03152318n=62

Feb 2027

Est. completion

P2Prostate Cancer Patients Treated by Radiotherapy

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000n=45

Oct 2031

Est. completion

P3Non-squamous, Non-Small Cell Lung Cancer

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

NCT07660094n=500

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Dec 2024

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

NCT04495153

Nov 2024

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363

Aug 2024

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

NCT01436968

Recent Press Releases

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

Nov 6, 2026 · GlobeNewsWire

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 5, 2026 · GlobeNewsWire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 2, 2026 · GlobeNewsWire

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

Oct 29, 2026 · GlobeNewsWire

Candel Therapeutics to Present at November Investor Conferences

Oct 27, 2026 · GlobeNewsWire

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Oct 22, 2026 · GlobeNewsWire

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Oct 2, 2026 · GlobeNewsWire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2026 · GlobeNewsWire

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Oct 1, 2026 · GlobeNewsWire

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Sep 30, 2026 · GlobeNewsWire

SEC Filings (66)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Sep 10, 2026	8-K	Material event	Document Index
Sep 9, 2026	8-K	Material event	Document Index
Aug 13, 2026	10-Q	Quarterly report	Document Index
Aug 13, 2026	8-K	Material event	Document Index
Jul 27, 2026	SC 13G	Passive 5%+ stake	Document Index
Jun 24, 2026	8-K	Material event	Document Index
Jun 16, 2026	8-K	Material event	Document Index
May 15, 2026	8-K	Material event	Document Index
May 15, 2026	SC 13G	Passive 5%+ stake	Document Index
May 14, 2026	10-Q	Quarterly report	Document Index
May 14, 2026	8-K	Material event	Document Index
Apr 29, 2026	ARS	Annual report to holders	Document Index
Apr 29, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Apr 29, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Apr 27, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Mar 18, 2026	SC 13D/A	Activist / 5%+ stake	Document Index
Mar 12, 2026	S-8	Employee stock plan	Document Index
Mar 12, 2026	10-K	Annual report	Document Index
Mar 12, 2026	8-K	Material event	Document Index
Feb 23, 2026	8-K	Material event	Document Index
Feb 20, 2026	424B5	Offering prospectus	Document Index
Feb 19, 2026	424B5	Offering prospectus	Document Index
Feb 19, 2026	8-K	Material event	Document Index
Jan 21, 2026	SC 13G	Passive 5%+ stake	Document Index
Dec 5, 2025	8-K	Material event	Document Index
Nov 13, 2025	10-Q	Quarterly report	Document Index
Nov 13, 2025	8-K	Material event	Document Index
Oct 14, 2025	8-K	Material event	Document Index
Aug 22, 2025	EFFECT		Document Index
Aug 21, 2025	8-K	Material event	Document Index
Aug 14, 2025	S-3	Shelf registration	Document Index
Aug 14, 2025	10-Q	Quarterly report	Document Index
Aug 14, 2025	8-K	Material event	Document Index
Jun 30, 2025	SC 13G	Passive 5%+ stake	Document Index
Jun 24, 2025	8-K	Material event	Document Index
Jun 24, 2025	424B5	Offering prospectus	Document Index
Jun 23, 2025	8-K	Material event	Document Index
Jun 18, 2025	8-K	Material event	Document Index
Jun 6, 2025	8-K	Material event	Document Index
May 28, 2025	8-K	Material event	Document Index